DOP2015000055A - Etanercept correctamente plegado de alta pureza y excelente rendimiento - Google Patents
Etanercept correctamente plegado de alta pureza y excelente rendimientoInfo
- Publication number
- DOP2015000055A DOP2015000055A DO2015000055A DO2015000055A DOP2015000055A DO P2015000055 A DOP2015000055 A DO P2015000055A DO 2015000055 A DO2015000055 A DO 2015000055A DO 2015000055 A DO2015000055 A DO 2015000055A DO P2015000055 A DOP2015000055 A DO P2015000055A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- etanercept
- correctly folded
- high purity
- folded
- preparations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Método de cromatografía de modo mixto para separar las conformaciones correctamente plegadas de las incorrectamente plegadas de una proteína dada. El método es muy eficaz en la separación de etanercept correctamente plegado del etanercept incorrectamente plegado y de agregados con rendimientos comercialmente atractivos que permiten obtener preparaciones de etanercept de una muy alta pureza en términos de etanercept correctamente plegado versus etanercept incorrectamente plegado. La invención está dirigida además a preparaciones de proteínas y formulaciones que comprenden proteínas correctamente plegadas obtenidas usando los métodos de la presente, y métodos de tratamiento que emplean las preparaciones de gran pureza obtenidas del método de modo mixto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699552P | 2012-09-11 | 2012-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2015000055A true DOP2015000055A (es) | 2015-04-30 |
Family
ID=50233493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2015000055A DOP2015000055A (es) | 2012-09-11 | 2015-03-10 | Etanercept correctamente plegado de alta pureza y excelente rendimiento |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US20140072560A1 (es) |
| EP (1) | EP2895188B1 (es) |
| JP (3) | JP2015533797A (es) |
| KR (2) | KR102250937B1 (es) |
| CN (2) | CN104902914B (es) |
| AR (1) | AR092532A1 (es) |
| AU (2) | AU2013315750B9 (es) |
| BR (1) | BR112015005161A2 (es) |
| CA (1) | CA2882551A1 (es) |
| CL (1) | CL2015000572A1 (es) |
| CO (1) | CO7400876A2 (es) |
| CY (1) | CY1120062T1 (es) |
| DK (1) | DK2895188T3 (es) |
| DO (1) | DOP2015000055A (es) |
| EA (1) | EA031324B1 (es) |
| EC (1) | ECSP15014138A (es) |
| ES (1) | ES2657377T3 (es) |
| HR (1) | HRP20180182T1 (es) |
| HU (1) | HUE036524T2 (es) |
| IL (2) | IL237311B (es) |
| IN (1) | IN2015KN00452A (es) |
| LT (1) | LT2895188T (es) |
| MX (2) | MX360044B (es) |
| NO (1) | NO2972131T3 (es) |
| PE (2) | PE20150996A1 (es) |
| PL (1) | PL2895188T3 (es) |
| PT (1) | PT2895188T (es) |
| RS (1) | RS57013B1 (es) |
| SG (1) | SG11201501460RA (es) |
| SI (1) | SI2895188T1 (es) |
| TW (2) | TWI609877B (es) |
| WO (1) | WO2014043103A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS |
| SG11201401562RA (en) | 2011-10-18 | 2014-09-26 | Coherus Biosciences Inc | Etanercept formulations stabilized with sodium chloride |
| US10485869B2 (en) | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
| ES2657377T3 (es) * | 2012-09-11 | 2018-03-05 | Coherus Biosciences, Inc. | Etanercept plegado correctamente con alta pureza y excelente rendimiento |
| CA2951766A1 (en) * | 2014-06-13 | 2015-12-17 | Lupin Limited | Process for the purification of tnfr:fc fusion protein |
| EP2975050B1 (en) | 2014-07-18 | 2019-05-29 | Sandoz Ag | Quantification of misfolded TNFR2:Fc |
| MX2017008633A (es) * | 2014-12-31 | 2018-04-26 | Lg Chemical Ltd | Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas. |
| KR20170138426A (ko) | 2015-03-13 | 2017-12-15 | 삼성바이오에피스 주식회사 | 항-tnf-알파 폴리펩티드 조성물 및 그 용도 |
| WO2017084738A1 (en) * | 2015-11-18 | 2017-05-26 | Merck Patent Gmbh | Opposite ph-salt gradients for improved protein separations |
| AU2016355739A1 (en) * | 2015-11-18 | 2018-07-05 | Merck Patent Gmbh | Improved protein separation in ion exchange chromatography |
| CN109563124A (zh) * | 2016-06-17 | 2019-04-02 | 豪夫迈·罗氏有限公司 | 多特异性抗体的纯化 |
| JP6884858B2 (ja) | 2016-10-21 | 2021-06-09 | アムジエン・インコーポレーテツド | 医薬製剤及びその製造方法 |
| KR20190131082A (ko) * | 2017-03-24 | 2019-11-25 | 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 | 재조합 항체 단편을 정제하는 방법 |
| US11253569B2 (en) | 2018-05-03 | 2022-02-22 | Seattle Children's Hospital | Methods of treating Kawasaki Disease |
| CN112876567A (zh) * | 2019-11-29 | 2021-06-01 | 广东菲鹏制药股份有限公司 | Fc融合蛋白及其纯化方法 |
| CA3213505A1 (en) * | 2021-03-16 | 2022-09-22 | Kashiv Biosciences, Llc | Novel formulation of fusion protein |
| WO2022234412A1 (en) * | 2021-05-03 | 2022-11-10 | Lupin Limited | A process for purification of fc-fusion proteins |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| EP1132471A3 (de) | 1989-09-12 | 2001-11-28 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
| IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
| ES2120949T4 (es) | 1990-06-28 | 2011-12-29 | Sanofi-Aventis Deutschland Gmbh 50% | Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo. |
| WO1994006476A1 (en) | 1992-09-15 | 1994-03-31 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US7294481B1 (en) | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
| US20010021380A1 (en) | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| WO2000062790A2 (en) | 1999-04-19 | 2000-10-26 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| MXPA02007683A (es) | 2000-02-10 | 2002-12-13 | American Home Prod | Metodo para tratar o inhibir la lesion celular o muerte celular. |
| ES2644275T3 (es) | 2000-08-11 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen anticuerpos |
| EE200300408A (et) | 2001-02-23 | 2003-12-15 | Immunex Corporation | Aktiivsete valkude saagise suurendamine |
| ES2311094T3 (es) * | 2002-02-27 | 2009-02-01 | Immunex Corporation | Composicion estabilizada de tnfr-fc que comprende arginina. |
| WO2004017955A1 (en) * | 2002-08-22 | 2004-03-04 | Vasopharm Biotech Gmbh | L-arginine containing pharmaceutical composition |
| US20040115263A1 (en) | 2002-08-26 | 2004-06-17 | Robertson David W. | Use of bupropion for treating restless legs syndrome |
| JP4980048B2 (ja) | 2003-02-28 | 2012-07-18 | アレス トレーディング ソシエテ アノニム | 腫瘍壊死因子結合タンパク質の液体製剤 |
| EP1607103A1 (en) | 2003-03-20 | 2005-12-21 | Eisai Co., Ltd. | Concomitant drug as therapeutic agent for inflammatory bowel disease |
| BRPI0413197A (pt) | 2003-08-01 | 2006-10-03 | Amgen Inc | cristal de eta wercept; método para fabricar um cristal de etanercept; composição; uso de um cristal de etanercept |
| NZ546347A (en) | 2003-10-14 | 2009-11-27 | Intermune Inc | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication |
| EP1718386A1 (en) * | 2004-02-27 | 2006-11-08 | GE Healthcare Bio-Sciences AB | A process for the purification of antibodies |
| JP5554466B2 (ja) | 2004-03-01 | 2014-07-23 | 味の素株式会社 | 抗ヒトＴＮＦ−α抗体活性低下抑制剤 |
| EP2308958A3 (en) | 2004-03-05 | 2011-08-10 | DSM IP Assets B.V. | Process for cell culturing by continuous perfusion and alternating tangential flow |
| US20070196364A1 (en) | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
| TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| JP5339901B2 (ja) | 2005-05-10 | 2013-11-13 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 炎症傷害の処置および評価 |
| KR101367544B1 (ko) | 2005-06-10 | 2014-02-26 | 추가이 세이야쿠 가부시키가이샤 | 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용 |
| WO2007076354A2 (en) | 2005-12-20 | 2007-07-05 | Bristol-Myers Squibb Company | Stable protein formulations |
| CN101378782A (zh) | 2005-12-21 | 2009-03-04 | 惠氏公司 | 粘度降低的蛋白质制剂及其用途 |
| JP2009525986A (ja) | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| JP5374359B2 (ja) | 2006-03-17 | 2013-12-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 安定化されたポリペプチド化合物 |
| US20080003220A1 (en) | 2006-04-21 | 2008-01-03 | Amgen, Inc. | Buffering agents for biopharmaceutical formulations |
| EP2081553B1 (en) | 2006-10-06 | 2020-08-12 | Amgen Inc. | Stable antibody formulations |
| EP2094247B1 (en) | 2006-10-20 | 2022-06-29 | Amgen Inc. | Stable polypeptide formulations |
| EP2395077A1 (en) | 2006-11-03 | 2011-12-14 | Wyeth LLC | Glycolysis-inhibiting substances in cell culture |
| CA2672902C (en) | 2006-12-21 | 2012-11-27 | Amgen Inc. | Formulations |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| AU2008223133A1 (en) | 2007-03-02 | 2008-09-12 | Wyeth | Use of copper and glutamate in cell culture for production of polypeptides |
| EP2014760A1 (en) | 2007-06-13 | 2009-01-14 | CMC Biopharmaceuticals A/S | A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process |
| PL2170390T3 (pl) | 2007-06-14 | 2019-05-31 | Biogen Ma Inc | Preparaty przeciwciała natalizumab |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| US20110129468A1 (en) * | 2008-02-29 | 2011-06-02 | Biogen Idec Ma Inc. | Purified immunoglobulin fusion proteins and methods of their purification |
| JP5677943B2 (ja) * | 2008-06-05 | 2015-02-25 | アフィボディ・アーベーＡｆｆｉｂｏｄｙ Ａｂ | ポリペプチド |
| WO2011015926A1 (en) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein |
| US8536316B2 (en) | 2009-08-07 | 2013-09-17 | Emd Millipore Corporation | Methods for purifying a target protein from one or more impurities in a sample |
| SG10201901417UA (en) | 2009-08-11 | 2019-03-28 | Genentech Inc | Production of proteins in glutamine-free cell culture media |
| WO2011049798A1 (en) * | 2009-10-20 | 2011-04-28 | Merck Sharp & Dohme Corp. | Use of mixed mode chromatography for the capture and purification of basic antibody products |
| WO2011079308A2 (en) | 2009-12-23 | 2011-06-30 | Emergent Product Development Seattle, Llc | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
| SG185038A1 (en) | 2010-04-26 | 2012-11-29 | Novartis Ag | Improved cell culture medium |
| WO2011141926A2 (en) * | 2010-05-10 | 2011-11-17 | Intas Biopharmaceuticals Limited | Liquid formulation of polypeptides containing an fc domain of an immunoglobulin |
| US20130209465A1 (en) | 2010-07-30 | 2013-08-15 | Arecor Ltd. | Stabilized Aqueous Antibody Compositions |
| WO2012023085A1 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
| KR20130101034A (ko) | 2010-08-31 | 2013-09-12 | 프리슬랜드 브랜즈 비브이 | 진핵 세포를 위한 배양 배지 |
| CA2813747A1 (en) * | 2010-10-11 | 2012-04-19 | Chen Wang | Processes for purification of proteins |
| AU2012244764B2 (en) | 2011-04-20 | 2016-10-13 | Sandoz Ag | Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc |
| UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| EA026226B1 (ru) | 2011-07-01 | 2017-03-31 | Байоджен Айдек Ма Инк. | Не содержащие аргинина композиции слитого fc-полипептида и способы их применения |
| KR102558247B1 (ko) | 2011-07-01 | 2023-07-24 | 암젠 인크 | 포유동물 세포 배양 |
| JP6280499B2 (ja) * | 2011-07-08 | 2018-02-14 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｆｃ融合タンパク質の精製方法 |
| EP2753634B1 (en) | 2011-08-17 | 2017-11-01 | Ares Trading S.A. | Method for preparing active form of tnfr-fc fusion protein |
| SG11201401562RA (en) * | 2011-10-18 | 2014-09-26 | Coherus Biosciences Inc | Etanercept formulations stabilized with sodium chloride |
| US10485869B2 (en) * | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
| CN104661651A (zh) * | 2012-07-09 | 2015-05-27 | 科荣生生物科学公司 | 表现出不溶性微粒显著减少的依那西普制剂 |
| ES2657377T3 (es) * | 2012-09-11 | 2018-03-05 | Coherus Biosciences, Inc. | Etanercept plegado correctamente con alta pureza y excelente rendimiento |
| CA2916836C (en) * | 2014-07-31 | 2017-12-12 | Mtt Innovation Incorporated | Numerical approaches for free-form lensing: area parameterization free-form lensing |
| US20160108634A1 (en) * | 2014-10-16 | 2016-04-21 | Ronald Uphold | Pool Cover Hanger Device |
-
2013
- 2013-09-10 ES ES13838016.7T patent/ES2657377T3/es active Active
- 2013-09-10 MX MX2015003090A patent/MX360044B/es active IP Right Grant
- 2013-09-10 SI SI201330936T patent/SI2895188T1/en unknown
- 2013-09-10 JP JP2015531311A patent/JP2015533797A/ja active Pending
- 2013-09-10 EP EP13838016.7A patent/EP2895188B1/en active Active
- 2013-09-10 AU AU2013315750A patent/AU2013315750B9/en not_active Ceased
- 2013-09-10 EA EA201590542A patent/EA031324B1/ru unknown
- 2013-09-10 IN IN452KON2015 patent/IN2015KN00452A/en unknown
- 2013-09-10 RS RS20180095A patent/RS57013B1/sr unknown
- 2013-09-10 PT PT138380167T patent/PT2895188T/pt unknown
- 2013-09-10 CN CN201380058650.5A patent/CN104902914B/zh not_active Expired - Fee Related
- 2013-09-10 PE PE2015000316A patent/PE20150996A1/es unknown
- 2013-09-10 SG SG11201501460RA patent/SG11201501460RA/en unknown
- 2013-09-10 BR BR112015005161A patent/BR112015005161A2/pt not_active Application Discontinuation
- 2013-09-10 CN CN201811633164.2A patent/CN110051823A/zh active Pending
- 2013-09-10 KR KR1020207019733A patent/KR102250937B1/ko active IP Right Grant
- 2013-09-10 PL PL13838016T patent/PL2895188T3/pl unknown
- 2013-09-10 PE PE2019002512A patent/PE20200607A1/es unknown
- 2013-09-10 LT LTEP13838016.7T patent/LT2895188T/lt unknown
- 2013-09-10 CA CA2882551A patent/CA2882551A1/en active Pending
- 2013-09-10 KR KR1020157009386A patent/KR102133699B1/ko active IP Right Grant
- 2013-09-10 HU HUE13838016A patent/HUE036524T2/hu unknown
- 2013-09-10 WO PCT/US2013/058994 patent/WO2014043103A1/en active Application Filing
- 2013-09-10 DK DK13838016.7T patent/DK2895188T3/en active
- 2013-09-11 US US14/023,736 patent/US20140072560A1/en not_active Abandoned
- 2013-09-11 AR ARP130103250A patent/AR092532A1/es not_active Application Discontinuation
- 2013-09-11 TW TW102132831A patent/TWI609877B/zh active
- 2013-09-11 TW TW106136921A patent/TWI716649B/zh active
-
2014
- 2014-03-13 NO NO14719160A patent/NO2972131T3/no unknown
-
2015
- 2015-02-19 IL IL237311A patent/IL237311B/en active IP Right Grant
- 2015-03-06 CL CL2015000572A patent/CL2015000572A1/es unknown
- 2015-03-10 MX MX2018012749A patent/MX2018012749A/es unknown
- 2015-03-10 DO DO2015000055A patent/DOP2015000055A/es unknown
- 2015-04-07 CO CO15076746A patent/CO7400876A2/es unknown
- 2015-04-10 EC ECIEPI201514138A patent/ECSP15014138A/es unknown
-
2017
- 2017-09-29 US US15/720,291 patent/US11001627B2/en active Active
-
2018
- 2018-01-31 HR HRP20180182TT patent/HRP20180182T1/hr unknown
- 2018-02-13 CY CY20181100172T patent/CY1120062T1/el unknown
- 2018-10-10 AU AU2018247244A patent/AU2018247244B2/en not_active Ceased
- 2018-10-11 JP JP2018192476A patent/JP6913066B2/ja active Active
-
2019
- 2019-06-17 US US16/443,721 patent/US10954295B2/en active Active
- 2019-06-17 US US16/443,514 patent/US10954293B2/en active Active
- 2019-06-17 US US16/443,688 patent/US10947306B2/en active Active
- 2019-06-17 US US16/443,594 patent/US10954294B2/en active Active
- 2019-06-18 IL IL267452A patent/IL267452B/en active IP Right Grant
-
2021
- 2021-02-22 JP JP2021025939A patent/JP2021100929A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2015000055A (es) | Etanercept correctamente plegado de alta pureza y excelente rendimiento | |
| CY1121989T1 (el) | Φαρμακοτεχνικες μορφες αντισωματων | |
| CO2020001872A2 (es) | Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana | |
| CY1125392T1 (el) | Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων | |
| CY1119576T1 (el) | Ν-ακυλ-(3-υποκατεστημενες)-(8-υποκατεστημενες)-5,6-διϋδρο-[1,2,4]τριαζολο[4,3-α]πυραζινες ως επιλεκτικοι ανταγωνιστες του υποδοχεα νκ-3, φαρμακευτικη συνθεση, μεθοδοι για χρηση σε διαμεσολαβουμενες απο τον υποδοχεα νκ-3 διαταραχες | |
| EA201391597A1 (ru) | Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки | |
| EA201791507A1 (ru) | Пирроло- и пиразолопиримидины в качестве ингибиторов убиквитин- специфичной протеазы 7 | |
| AR092050A1 (es) | Proteinas de fusion de anticuerpos e interleuquina 10 y usos de las mismas | |
| EA201690093A1 (ru) | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний | |
| BR112015020389A2 (pt) | compostos carbazol úteis como inibidores de bromodomínio | |
| BR112015022191A2 (pt) | compostos heteroarila, seu uso e composição que os compreende | |
| EA201591524A1 (ru) | Производные 2-аминопиримидина для лечения вирусных инфекций | |
| EA201690898A1 (ru) | Способы лечения таупатии | |
| EA201492216A1 (ru) | Ингибиторы бромодомена и их применение | |
| EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| CR20140175A (es) | Compuestos y métodos para mejorar las respuestas inmunitarias innatas | |
| EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
| WO2014141152A3 (en) | Low concentration antibody formulations | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| CO6781540A2 (es) | Protéinas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae | |
| EA201391632A1 (ru) | Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды | |
| CR20160222U (es) | Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas | |
| EA201591501A1 (ru) | Терапевтические средства на основе csf-1 | |
| CY1121895T1 (el) | Σκευασματα διαλυματος κατασκευασμενων αντισωματων anti-il-23p19 | |
| MD20150109A2 (ro) | Construcţii proteice mitocondriale şi utilizările acestora |